Please login to the form below

Not currently logged in
Email:
Password:

cHL

This page shows the latest cHL news and features for those working in and with pharma, biotech and healthcare.

Keytruda doubles five-year survival rate in NSCLC

Keytruda doubles five-year survival rate in NSCLC

Since then, the immunotherapy has added an array of indications to its arsenal, including approvals for the treatment of head and neck squamous cell carcinoma, classical Hodgkin lymphoma (cHL), cervical cancer,

Latest news

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) – a niche indication not yet taken in China by Keytruda and Opdivo, which

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics